Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Shimadzu UK Launches LCMS-8080

Published: Monday, December 31, 2012
Last Updated: Monday, December 31, 2012
Bookmark and Share
Offers best-in-class sensitivity, high quality data and fast cycle times.

Shimadzu UK has launched a high-end liquid chromatography mass spectrometer - the LCMS-8080 - which delivers best-in-class sensitivity, high quality data and fast cycle times.

An extension of its Ultra Fast Mass Spectrometry (UFMS) range, the new model’s high speed capabilities increase productivity in the laboratory by delivering accurate measurements, first time.

Ideal for users requiring information rich analyses, the LCMS-8080 can be used across a wide range of applications including food safety testing, drugs of abuse screening as well as in clinical, environmental and ADME laboratories.

The instrument delivers high quality and accurate data over long periods of use due to its simple and rapid method development.

The innovative Coaxial Hot Gas Desolvation source is fundamental in delivering the LCMS-8080’s enhanced sensitivity as it focuses the ion plume and improves ionization efficiency.

This is further enhanced by Hot Source Induced Desolvation which removes solvent noise, followed by high performance pumping and a multi-orthogonal inlet.

The LCMS-8080’s class-leading sensitivity allows accurate quantitation of low level analytes Plus, the model provides outstanding ruggedness when measuring target compounds in complex matrices.

Its compact footprint frees up the use of costly lab space, while its robust characteristics increase uptime by reducing instrument down time.

Shimadzu offers prepackaged methods to enable rapid installation of the LCMS-8080. This means that individual components can easily be reused when new methods have been developed, which reduces the amount of rework necessary and boosts productivity.

Shimadzu’s software is purpose built for chromatography and quantitation, providing a single platform for Shimadzu’s liquid chromatography (LC), gas chromatography (GC), LCMS and GCMS.

The intuitive and unified operation flow and new functionalities enable more efficient data processing. Analyses which use both GC-MS/MS and LC-MS/MS for the same sample, such as multi-target quantitative analysis in food safety testing, benefit from the unified graphical user interface of software which reduces training needs across the laboratory and minimizes the total cost of ownership.

The LCMS-8080 is compatible with Nexera UHPLC which offers high carryover specifications and the highest pressure rating of any UHPLC.

Users can be confident in the analyses as the high end instrument delivers offers excellent stability and reliability in data acquisition, even when rapidly switching the ionization polarity.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

‘Sharing Best Practice’ Events at Shimadzu University Help Participants Improve their Research Methods
The Shimadzu University recently held a series of complimentary ‘Sharing best practice’ events for any Shimadzu customers interested in learning more about how to get the most reliable results from their methods.
Thursday, January 24, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos